Sonic Healthcare delivered full-year results to June 2026 that met guidance and demonstrated solid operational execution across its sprawling international platform. Revenue grew 13% to $10.87 billion, underpinned by organic growth of 5%, while underlying EBITDA increased 11% to $1.93 billion and underlying earnings per share climbed 14% to 125.6 cents. The result reflects the company’s ability to drive earnings growth through its diversified global footprint, recent acquisitions in Germany and Switzerland, and growing demand for advanced diagnostics services.
The pathway to earnings growth was multifaceted. Organic expansion of 5% shows core market momentum, while acquisition-driven growth contributed the remaining 8% of revenue gains. The LADR Laboratory Group acquisition in North America, completed during the year, is already integrating and delivering expected synergies. Sonic also continued to harvest significant synergy benefits from earlier acquisitions in Switzerland and Germany, demonstrating management’s operational capabilities and integration discipline. The company serves over 140 million patients annually across nine countries and eleven markets, positioning it as one of the world’s largest diagnostics operators by volume and reach.
Management highlighted strong momentum in advanced diagnostics, a higher-margin segment that should drive both revenue and profitability expansion over time. The company completed a sale and leaseback of its Brisbane hub laboratory, a disciplined capital management move that likely monetized underutilized real estate while retaining operational control. At the same time, Sonic initiated a comprehensive operating review of its United States business and commenced a significant digital and AI transformation program, both of which suggest management sees efficiency gains and technology-driven opportunities ahead.
The dividend policy reinforced confidence in cash generation. Sonic increased total dividends by 1 cent to $1.08 per share for the year, maintaining its progressive track record while preserving capital for growth investment. This strikes a reasonable balance between rewarding shareholders and retaining firepower for acquisitions or organic initiatives.
Investors should monitor several items going forward. The integration of LADR and the realization of synergy targets will be critical to validate management’s acquisition strategy and integration capabilities. The United States operating review may reveal restructuring charges or efficiency initiatives that reshape earnings near-term. The digital and AI transformation program is nascent but could be transformational if execution matches ambition, particularly in automating diagnostics workflows and improving efficiency. Additionally, any material movement in diagnostic volumes, pricing power, or private healthcare utilization rates in key markets will significantly impact earnings trajectory.
Sonic Healthcare’s stock is materially price sensitive under ASX listing rules, and this announcement has been flagged as material by the exchange.
View the full ASX announcement (PDF)
About Sonic Healthcare Limited (ASX: SHL)
Sonic Healthcare Limited is a global healthcare provider operating the largest private medical laboratory and pathology services in Australia, the United Kingdom, Germany, and Switzerland. The company generates approximately 85% of its revenue from pathology services and is also the second-largest operator of diagnostic imaging services in Australia and the largest operator of medical centers in Australia.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
